Cancer diagnostics News and Research

RSS

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

OVA1™, the first blood test cleared by the U.S. Food and Drug Administration (FDA) for aiding in the pre-surgical evaluation of a woman's ovarian mass for cancer, is now available nationally through Quest Diagnostics, Inc., the world's leading cancer diagnostics provider.

From Quest Diagnostics 10 Mar 2010

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

New research published in today's issue of the Archives of Internal Medicine (Vol. 170, No. 5), by an investigator at The Cancer Institute of New Jersey and colleagues at Memorial Sloan-Kettering Cancer Center in New York, shows that the type of specialist that men with localized prostate cancer see can influence the form of therapy they ultimately receive.

9 Mar 2010

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

DiagnoCure, Inc., a life sciences company commercializing high-value cancer diagnostic tests and delivering laboratory services, announced that the clinical utility of the PROGENSA(R) PCA3 test, developed and commercialized by its partner Gen-Probe, was confirmed in two large worldwide studies, conducted in a subset of patients in GlaxoSmithKline's REDUCE trial of dutasteride. The results demonstrate that PCA3 can help determine whether men suspected of having prostate cancer should undergo a repeat biopsy and can predict the risk of having an aggressive cancer.

8 Mar 2010

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

Breast cancer patients with early stage disease that has spread to only one lymph node may not benefit from radiation after mastectomy, because of the low present-day risk of recurrence following modern surgery and systemic therapy, a finding that could one day change the course of treatment for thousands of women diagnosed each year, according to researchers at The University of Texas M. D. Anderson Cancer.

7 Mar 2010

New guidance produced to help GPs identify symptoms of cervical cancer in young women

New guidance has been produced to help GPs identify symptoms of cervical cancer and facilitate early diagnosis of the disease in young women.

6 Mar 2010

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

Abbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a molecular diagnostic test intended for use as an aid in selecting patients who may benefit from a skin cancer treatment in development by GSK.

4 Mar 2010

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Responding to continued debate over PSA screening, and today’s American Cancer Society statement, the Prostate Cancer Foundation reiterated its position that PSA screening remains a valuable tool, in combination with other tools, for identifying potential prostate disease, including cancer.

4 Mar 2010

Research explores the importance of patient's outlook on health behavior and health status

Research published in the March edition of the Journal of Thoracic Oncology explored the importance of a patient's outlook as it relates to health behavior and health status. Researchers focused on lung cancer patients and discovered that those who exhibited an optimistic disposition experienced more favorable outcomes than those with a pessimistic disposition.

4 Mar 2010

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

An imaging technique combining ultrasound and specially modified contrast agents may allow researchers to noninvasively detect cancer and show its progression, according to research published in the March issue of The Journal of Nuclear Medicine (JNM). The technique enables researchers to visualize tumor activity at the molecular level.

2 Mar 2010

GenWay Biotech's simple blood sample cancer assessment test

San Diego-based GenWay Biotech, Inc. today announced the availability of the You Test You- Cancer Assessment that allows patients to test for various types of cancer without having to visit their doctor's office, through a simple blood sample. With a 10-day turnaround time and a cost of $149, You Test You- is a convenient and low cost way to periodically test for indication of cancer.

2 Mar 2010

Study evaluates possible diet associations with ovarian cancer survival

2009 estimates projected that in the United States alone 21,550 new cases of ovarian cancer would be diagnosed and 14,600 women would die of the disease. Often diagnosed in late stages, ovarian cancer has an asymptomatic onset and a relatively low 5-year survival rate of about 45%. Consequently investigation linked to survivorship is critical.

1 Mar 2010

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

A recent Avon Foundation for Women survey confirms what the American College of Radiology and other experts warned would happen: states are using deeply flawed and widely discredited U.S. Preventative Services Task Force mammography recommendations to deny women coverage for mammograms, and many women are foregoing long proven, life-saving mammography care based on the mistaken USPSTF recommendations.

23 Feb 2010

WCMC-Q students receive new round of UREP funds totaling $280,000

Twenty-eight WCMC-Q students have received grants totaling $280,000 in the latest, seventh, round of funding from the Undergraduate Research Experience Program (UREP) to conduct advanced research projects with faculty members.

22 Feb 2010

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Genoptix, Inc., a specialized laboratory service provider, and HistoRx, Inc. (privately held), a diagnostics company, today announced a multi-year licensing agreement for AQUA® technology and several diagnostic assays based on it.

19 Feb 2010

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

One in eight women diagnosed with breast cancer is younger than 45 when diagnosed, yet their emotional and medical concerns are different than those of women over age 45, as is the impact of their diagnosis on family, friends, partners, colleagues and children.

18 Feb 2010

New conference to discuss issues surrounding breast cancer to take place at UWE

An opportunity to join a forum to discuss issues surrounding breast cancer is taking place at the University of the West of England on Saturday 3 July 2010.

15 Feb 2010

Research roundup: Bundled payments, PTSD incidence, cost of treating immigrants

This paper examines the spending for health care of adult naturalized citizens and immigrant noncitizens (including some undocumented immigrants) compared to U.S. natives, as documented in data from the 1999-2006 Medical Expenditure Panel Surveys (MEPS): "inflation and age-adjusted health care expenditures among noncitizen immigrants were consistently … lower than those of naturalized citizens and U.S. natives during 1999-2006."

15 Feb 2010

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ has opened up the path to femtomedicine, an entirely new cancer diagnostics, it was reported today at First Global Congress on NanoEngineering for Medicine and Biology in Houston, TX.

10 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

US HIFU announces exclusive partnership with Riverside Research Institute

US HIFU, a worldwide leader in the development, distribution and use of minimally invasive high intensity focused ultrasound (HIFU) technologies, announced today its exclusive partnership with Riverside Research Institute (RRI) to develop and test an ultrasonic method of prostate imaging and treatment that combines advanced tissue-type imaging with ultrasound energy from the Sonablate® 500 medical device.

10 Feb 2010

Cancer diagnostics News and Research

OVA1 blood test aids in pre-surgical evaluation of women for ovarian cancer now available through Quest Diagnostics

Type of specialist that men with prostate cancer see can influence form of therapy they ultimately receive

DiagnoCure: Global studies confirm clinical utility of PROGENSA PCA3 test

Breast cancer patients with early stage disease may not benefit from radiation after mastectomy

New guidance produced to help GPs identify symptoms of cervical cancer in young women

Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatment

PCF: PSA screening remains valuable tool for identifying potential prostate disease

Research explores the importance of patient's outlook on health behavior and health status

Imaging technique combining ultrasound and microscopic bubbles help visualize tumor activity at molecular level

GenWay Biotech's simple blood sample cancer assessment test

Study evaluates possible diet associations with ovarian cancer survival

USPSTF mammography recommendations: Avon Foundation for Women survey confirms states denying coverage

WCMC-Q students receive new round of UREP funds totaling $280,000

Genoptix signs multi-year licensing agreement with HistoRx for AQUA technology

Medical experts convene to discuss emotional and medical issues of young breast cancer survivors

New conference to discuss issues surrounding breast cancer to take place at UWE

Research roundup: Bundled payments, PTSD incidence, cost of treating immigrants

Bombarding DNA nucleotides and mammalian meat with ‘femto-neutrons’ open new path to femtomedicine

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

US HIFU announces exclusive partnership with Riverside Research Institute

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News